Agile Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:31 pm EST
Share
Agile Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 6.66 million compared to USD 3 million a year ago. Net loss was USD 0.799 million compared to USD 5.93 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 8.01 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to USD 8.01 a year ago.
For the nine months, sales was USD 15.98 million compared to USD 6.89 million a year ago. Net loss was USD 10 million compared to USD 21.48 million a year ago. Basic loss per share from continuing operations was USD 5.3 compared to USD 71.61 a year ago. Diluted loss per share from continuing operations was USD 5.3 compared to USD 71.61 a year ago.
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
AGILE THERAPEUTICS, INC. 
